The Leukemia & Lymphoma Society and the Institute for Follicular Lymphoma Innovation commit $20 million to jointly fund follicular lymphoma research.

白血病与淋巴瘤协会和滤泡性淋巴瘤创新研究所承诺提供2000万美元，共同资助滤泡性淋巴瘤研究。

RYE BROOK, N.Y., June 3, 2024 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Institute for Follicular Lymphoma Innovation (IFLI) today announce a new partnership on a $20-million initiative to fund research in follicular lymphoma, the most common slow-growing non-Hodgkin's lymphoma.

纽约州莱伊布鲁克（RyeBrook），2024年6月3日（PRNewswire）--白血病与淋巴瘤协会（LLS）和滤泡性淋巴瘤创新研究所（IFLI）今天宣布建立新的合作伙伴关系，以资助滤泡性淋巴瘤（最常见的生长缓慢的非霍奇金淋巴瘤）的研究。

The goal of the initiative, which will be named the Research Accelerator for Follicular Lymphoma (RAFL) Program, is to provide researchers with funding to identify how follicular lymphoma develops and create new therapies that better control and cure this blood cancer.

该倡议将被命名为滤泡性淋巴瘤研究加速器（RAFL）计划，其目标是为研究人员提供资金，以确定滤泡性淋巴瘤如何发展，并创造更好地控制和治愈这种血癌的新疗法。

'Cutting-edge technologies are redefining our approach to follicular lymphoma, setting new standards in both understanding and treatment,' says Michel Azoulay, M.D., MBA, the Institute for Follicular Lymphoma's Chief Medical Officer. 'The RAFL partnership, a collaborative effort between IFLI and LLS, is empowering researchers to lead the charge in breakthrough innovations.'.

滤泡性淋巴瘤研究所首席医疗官、MBA医学博士米歇尔·阿祖莱（MichelAzoulay）说，尖端技术正在重新定义我们治疗滤泡性淋巴瘤的方法，为理解和治疗树立新标准RAFL合作伙伴关系是IFLI和LLS之间的合作成果，它使研究人员能够领导突破性创新。”。

LLS and IFLI are committing to fund three types of competitive grants for selected innovative research programs in follicular lymphoma: a Synergistic Team Award, Translational Awards and Innovation Awards.

LLS和IFLI承诺为滤泡性淋巴瘤选定的创新研究项目提供三种类型的竞争性资助：协同团队奖、转化奖和创新奖。

Synergistic Team Award —This multi-investigator grant is designed to support a coordinated, focused and significant effort to understand the biology of follicular lymphoma and develop effective treatments for the disease. Multiple investigators from the same or different institutions working collaboratively will be eligible for this grant..

协同团队奖-这项多研究者资助旨在支持协调，集中和重大的努力，以了解滤泡性淋巴瘤的生物学并开发有效的疾病治疗方法。来自同一或不同机构的多名调查人员将有资格获得这笔赠款。。

Translational Awards — These grants aim to support clinical and/or biological research. The goal is to award these grants to researchers planning to conduct a clinical trial by year three of the grant.

转化奖-这些赠款旨在支持临床和/或生物学研究。目标是将这些赠款授予计划在赠款的第三年进行临床试验的研究人员。

Innovation Awards — These grants are intended to support projects that identify better ways to understand or treat follicular lymphoma.

创新奖-这些赠款旨在支持确定更好的方法来理解或治疗滤泡性淋巴瘤的项目。

These three grants are expected to be awarded over two different rounds: the Synergistic Team Award and two of the four Translational Awards would be conferred during the first round and the remaining Translational Awards and Innovation Awards would be granted during the second round.

这三项拨款预计将分两轮授予：第一轮授予协同团队奖和四项转化奖中的两项，其余转化奖和创新奖将在第二轮授予。

'This partnership between LLS and IFLI is a testament to our commitment to joining forces with like-minded organizations that share our goal of accelerating innovation that improves the lives of blood cancer patients,' says Lee Greenberger, Ph.D., Chief Scientific Officer at The Leukemia & Lymphoma Society..

白血病与淋巴瘤协会首席科学官Lee Greenberger博士说：“LLS与IFLI之间的这种合作证明了我们致力于与志同道合的组织携手合作，这些组织与我们有着共同的目标，即加速创新，改善血癌患者的生活。”。。

The RAFL Program expects to begin accepting grant applications by July 1, 2024, with the review process taking place in spring 2025.

RAFL计划预计将于2024年7月1日开始接受拨款申请，审查过程将于2025年春季进行。

About The Leukemia & Lymphoma Society

关于白血病和淋巴瘤协会

The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care..

白血病与淋巴瘤协会®（LLS）是全球抗击血癌的领导者。LLS的使命：治愈白血病、淋巴瘤、霍奇金病和骨髓瘤，提高患者及其家属的生活质量。LLS为世界各地的挽救生命的血癌研究提供资金，提供免费信息和支持服务，是所有寻求优质，负担得起，协调护理的血癌患者的声音。。

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

LLS成立于1949年，总部位于纽约州的莱伊布鲁克，在美国和加拿大拥有多个地区。要了解更多信息，请访问www.LLS.org。患者应联系信息资源中心，电话：（800）955-4572，周一至周五，美国东部时间上午9点至下午9点。

LLS stands out among brands around the world for its relevancy, cultural impact, ingenuity, and mission impact.

LLS以其相关性、文化影响力、独创性和使命影响力在世界各地的品牌中脱颖而出。

For additional information, visit lls.org/lls-newsnetwork. Follow us on Facebook, Twitter, and Instagram.

有关更多信息，请访问lls.org/lls-newsnetwork。在Facebook、Twitter和Instagram上关注我们。

About Institute for Follicular Lymphoma Innovation

关于滤泡性淋巴瘤创新研究所

The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma. IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of follicular lymphoma (FL), and to understand the biology of FL.

滤泡性淋巴瘤创新研究所（IFLI）是一个全球性的非营利性私人基金会，致力于加速为滤泡性淋巴瘤患者开发创新治疗方案。IFLI支持尖端研究和技术，以开发和商业化用于治疗滤泡性淋巴瘤（FL）的新型疗法和/或生物标志物，并了解FL的生物学。

The foundation deploys its budget across grants, project-based partnerships, and venture philanthropy investments to achieve its innovation goals. IFLI aims to promote collaboration, and enable the exchange of knowledge and expertise among researchers and institutions working on different aspects of FL research.

该基金会通过拨款、基于项目的合作伙伴关系和风险慈善投资来部署预算，以实现其创新目标。IFLI旨在促进合作，并使从事外语研究不同方面的研究人员和机构能够交流知识和专业知识。

Learn more at i-fli.org..

请访问i-fli.org了解更多信息。。

For Media Requests:

对于媒体请求：

LLS — Ryan McDonald, Ryan.McDonald@lls.org

LLS-Ryan McDonald，Ryan.McDonald@lls.org

IFLI — Klara Sol Sigurdardottir, klara@wtrshdcap.com

IFLI——Klara Sol Sigurdardottir，klara@wtrshdcap.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-20-million-research-funding-program-aims-to-accelerate-a-cure-for-follicular-lymphoma-302160831.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/new-20-million-research-funding-program-aims-to-accelerate-a-cure-for-follicular-lymphoma-302160831.html

SOURCE The Leukemia & Lymphoma Society

来源：白血病和淋巴瘤协会